Chronic ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) administration produces tolerance to cannabinoid effects, but alterations in signal transduction that mediate these changes are not yet known. 
Marijuana produces behavioral effects via its biologically active constituent ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) (Gaoni and Mechoulam, 1964; Deadwyler et al., 1995a) . Studies using potent synthetic cannabinoid analogs demonstrated that this activity occurs at cannabinoid receptors (Devane et al., 1988) . The cloned cannabinoid receptor exhibits seven transmembrane spanning regions characteristic of G-protein-coupled receptors (Matsuda et al., 1990) . Cannabinoid receptors act via G i/o to inhibit adenylyl cyclase (Howlett, 1985; Howlett et al., 1986; Pacheco et al., 1991) , alter potassium channel conductance , and decrease calcium channel conductance (Mackie and Hille, 1992) . Cannabinoid receptors in the brain (CB1) are numerous compared with other G-protein-coupled receptors and are localized in most brain regions, including the hippocampus, cortex, caudate-putamen, globus pallidus, substantia nigra, and cerebellum (Herkenham et al., 1991b; Jansen et al., 1992) . This anatomical distribution is consistent with behavioral effects of cannabinoids, including memory disruption, decreased motor activity, catalepsy, antinociception, and hypothermia (Dewey, 1986; Compton et al., 1993; Deadwyler et al., 1995a) .
Chronic ⌬ 9 -THC treatment results in the development of behavioral tolerance (Carlini, 1968; Dewey, 1986; Abood et al., 1993; Deadwyler et al., 1995b) . Some laboratories have reported a decrease in the B max of cannabinoid receptors after chronic ⌬ 9 -THC treatment (Oviedo et al., 1993; De Fonseca et al., 1994) , whereas others reported no change in cannabinoid receptor density (Westlake et al., 1991; Abood et al., 1993) . Moreover, changes in receptor binding may not reflect changes in receptor function, and a measurement of agonist efficacy is necessary to answer this question. In cultured neuroblastoma cells, chronic cannabinoid exposure desensitized cannabinoid-inhibited adenylyl cyclase (Dill and Howlett, 1988) , indicating that cannabinoid tolerance may involve alterations in signal transduction. Changes in G-protein activity and G-protein levels after chronic drug treatment have been reported previously for other receptor systems, including opioid receptors, which also couple to G i/o (Nestler et al., 1994; Sim et al., 1996a; Selley et al., 1996a) .
Our laboratory has developed a technique for examining receptor-activated G-proteins in brain sections using [ 35 S]GTP␥S autoradiography (Sim et al., 1995) . This technique is based on agonist-stimulated [
35 S]GTP␥S binding in membranes (Hilf et al., 1989; Traynor and Nahorski, 1995 (Sim et al., 1996a) . The present study was performed to examine the effect of chronic treatment with ⌬ 9 -THC on cannabinoid receptor-activated G-proteins in different brain regions. In addition to demonstrating that chronic ⌬ 9 -THC treatment produced large decreases in G-protein activation throughout the brain, these studies also reveal that ⌬ 9 -THC is a partial agonist in activating G-proteins in brain, which may have important implications in the mechanism of action of this drug.
MATERIALS AND METHODS
Materials. Male Sprague Dawley rats (200 -250 gm) were purchased from Zivic-Miller (Zelienople, PA). [
35 S]GTP␥S (1228 Ci/mmol) was purchased from New England Nuclear (Boston, MA). Baclofen and WIN 55212-2 were obtained from Research Biochemicals International (Natick, MA). ⌬ 9 -THC was provided by the National Institute on Drug Abuse. SR141716A was provided by Dr. F. Barth (Sanofi, Montpelier, France). GTP␥S and GDP for membrane assays were purchased from Boehringer Mannheim (New York, NY). GDP for autoradiography was obtained from Sigma (St. Louis, MO). Reflections autoradiography film was purchased from New England Nuclear. All other reagent grade chemicals were obtained from Sigma or Fisher Scientific (Houston, TX).
⌬ 9 -THC treatment. ⌬ 9 -THC was dissolved in ethanol and prepared for injection as described previously (Heyser et al., 1993) . The ethanol solution was suspended in a 1:4:1 ratio with Pluronic F68 detergent in ethanol and saline, and the ethanol was evaporated under a stream of nitrogen gas. The ⌬ 9 -THC was diluted to 10 mg/ml in saline for injection. Chronically treated animals received a single daily intraperitoneal injection of 10 mg/kg ⌬ 9 -THC for 21 d. Control animals received an equal volume of vehicle. Animals were killed 24 after the last injection. A separate group of animals received a single acute intraperitoneal injection of 10 mg/kg ⌬ 9 -THC or vehicle 24 hr before they were killed.
Agonist-stimulated [ 35 S]GTP␥S autoradiography. Animals were killed by rapid decapitation. Brains were removed and immediately immersed in isopentane at Ϫ35ЊC. Twenty micrometer horizontal sections were cut on a cryostat maintained at Ϫ20ЊC and mounted onto gelatin-subbed slides. Slides were incubated in assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, 0.5% BSA, pH 7.4) at 25ЊC for 10 min, and then in 2 mM GDP in assay buffer for 15 min at 25ЊC. Slides were then transferred into assay buffer containing 2 mM GDP and 0.04 nM [ 35 S]GTP␥S, with (stimulated) or without (basal) 10 M WIN 55212-2, and incubated at 25ЊC for 2 hr. Adjacent sections were incubated with 300 M baclofen and 0.04 nM [
35 S]GTP␥S to evaluate GABA B receptor activation of G-proteins. Sections from control animals were also processed using 1 or 10 M WIN 55212-2 and 3 or 10 M ⌬ 9 -THC alone and in combination. Slides were rinsed twice for 2 min each in 50 mM Tris-HCl buffer, pH 7.4, at 4ЊC, and once in deionized water, dried, and exposed to film for 48 hr. Films were digitized with a Sony XC-77 video camera and analyzed using the National Institutes of Health IMAGE program for Macintosh computers. Images were quantified by densitometric analysis with [
14 C] standards, and values were corrected to nanocuries/gram [ 35 S] based on a correction factor determined with brain paste standards (Sim et al., 1996a) . Data are mean values Ϯ SE of duplicate sections of brains from five animals. Statistical significance was determined by the nonpaired two tailed Student's t test using JMP (SAS Institute, Cary, NC).
Agonist-stimulated [ 35 S]GTP␥S binding in membranes. Cannabinoidstimulated [
35 S]GTP␥S binding was determined as described previously , using membranes from rat cerebellum (15 g protein). Membranes were incubated at 30ЊC for 1 hr in assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, 0.1 mg/ml BSA, pH 7.4), with the appropriate concentrations of WIN 55212-2 or ⌬ 9 -THC, in the presence of 20 M GDP and 0.05 nM [
35 S]GTP␥S in a 1 ml total volume. Basal binding was measured in the absence of agonist, and nonspecific binding was measured with 10 M GTP␥S. The reaction was terminated by rapid filtration under vacuum through Whatman GF/B filters, followed by three washes with cold Tris buffer. Bound radioactivity was determined by liquid scintillation spectrophotometry, at 95% efficiency for [ 35 S], after overnight extraction in 5 ml Ecolite scintillation fluid. Data are reported as mean Ϯ SE values of three experiments that were performed in triplicate. Nonlinear iterative regression analyses of agonist concentration-effect curves were performed with JMP (SAS, Cary, NC).
RESULTS

Effect of ⌬ 9 -THC on cannabinoid-stimulated [ 35 S]GTP␥S binding in cerebellar membranes and brain sections
Previous studies (Sim et al., 1995; Selley et al., 1996b; Sim et al., 1996b) have established that cannabinoid agonists stimulate [ 35 S]GTP␥S binding in both isolated membranes and brain sections, with a distribution and pharmacology that parallels that of cannabinoid receptor binding. To compare the effect of ⌬ 9 -THC and a more potent cannabinoid agonist in this assay system, concentration-effect curves of ⌬ 9 -THC-and WIN 55212-2-stimulated [
35 S]GTP␥S binding were generated in rat cerebellar membranes (Fig. 1 A) (Fig.  1 B) . The addition of 10 M WIN 55212-2 produced high levels of stimulated [
35 S]GTP␥S binding in the substantia nigra, entopeduncular nucleus, and globus pallidus, with moderate levels of activation in hippocampus and cortex. A maximally effective concentration of ⌬ 9 -THC alone (10 M) produced little stimulation of [ 35 S]GTP␥S binding. This concentration of ⌬ 9 -THC had no significant effect on 10 M WIN 55212-2-stimulated [
35 S]GTP␥S binding in the substantia nigra (Ͻ5% decrease by densitometric analysis) (Fig. 1 B) . In agreement with the membrane assays, however, this concentration of ⌬ 9 -THC visibly inhibited 
Effects of chronic and acute ⌬ 9 -THC administration on WIN 55212-2-stimulated [ 35 S]GTP␥S binding
To compare the effect of acute and chronic ⌬ 9 -THC administration on cannabinoid receptor activation of G-proteins, rats were treated with either a single acute dose of 10 mg/kg ⌬ 9 -THC or were administered daily injections of 10 mg/kg ⌬ 9 -THC for 21 d. The effect of ⌬ 9 -THC administration on cannabinoid-stimulated [ 35 S]GTP␥S binding was examined at four brain levels in horizontal sections from acute and chronic ⌬ 9 -THC-treated and control animals. Sections were analyzed at the level of (1) cerebellum, (2) caudate-putamen/septum, (3) globus pallidus, and (4) substantia nigra. At the most dorsal level, cannabinoid-stimulated [ 35 S]GTP␥S binding in control sections was observed in the cerebellum, hippocampus, and cortex. Labeling in all of these areas was visibly reduced in sections from chronic ⌬ 9 -THC-treated rats. At a more ventral level (Fig. 2, top) , cannabinoid-stimulated [ 35 S]GTP␥S binding was most evident in the cortex, hippocampus, caudate-putamen, septum, and periaqueductal gray (PAG), and was significantly reduced in sections from chronic ⌬ 9 -THCtreated rats. At the next level (Fig. 2, middle) , the reduction in cannabinoid-stimulated [
35 S]GTP␥S binding in the sections from chronic ⌬ 9 -THC-treated rats was most evident throughout the cortex, hippocampus, caudate-putamen, and globus pallidus. In the most ventral sections (Fig. 2, bottom) To quantify these effects, autoradiograms from all four groups of animals (acute and chronic ⌬ 9 -THC treated, and controls) were analyzed densitometrically. Figure 3 shows data from a number of brain regions in both acute and chronic groups, expressed as net nanocuries Figure 3A . These results demonstrated significant reductions in net binding in sections from chronic ⌬ 9 -THC-treated rats compared with controls, with Ͼ50% reduction in a number of regions, including the perirhinal cortex, entorhinal cortex, hippocampus, and cerebellum. Smaller but significant reductions in net agonist-stimulated [
35 S]GTP␥S binding were observed in the septum and caudate-putamen. The only region in which chronic ⌬ 9 -THC failed to significantly reduce net stimulated [
35 S]GTP␥S binding was the PAG; in this region, the level of net binding was reduced but failed to reach statistical significance. Figure 3B , shows net WIN 55212-2-stimulated [ 35 S]GTP␥S binding data from the same regions of acute ⌬ 9 -THC-treated animals, along with their respective controls. In contrast to the results observed with the chronic treatment group, acute ⌬ 9 -THC administration had no significant effect on net stimulated [
35 S]GTP␥S binding in any region measured. Because the levels of net stimulated [
35 S]GTP␥S binding in the globus pallidus and substantia nigra were much greater than those of the other regions, data from these regions are presented separately (Fig. 4) . As observed for other regions, net agoniststimulated [
35 S]GTP␥S binding was significantly reduced in chronic ⌬ 9 -THC-treated animals compared with controls, with 45% and 20% reductions in the globus pallidus and substantia nigra, respectively. On the other hand, no significant differences were found comparing net [
35 S]GTP␥S binding in these regions from acute ⌬ 9 -THC-treated and control rats (Fig. 4) . To determine the effect of acute and chronic ⌬ 9 -THC treatment on basal [
35 S]GTP␥S binding, Tables 1 and 2 present the densitometric data as percentages of the control basal values for each group. Table 1 shows the results comparing control and chronic ⌬ 9 -THC-treated animals, whereas Table 2 shows the results from the acute ⌬ 9 -THC-treated and control groups. In most regions studied, there was no significant effect of either chronic or acute ⌬ 9 -THC treatment on basal [ 35 S]GTP␥S binding. In the chronic group (Table 1) , the only exceptions were small decreases in basal binding in ventral caudate-putamen (15%) and globus pallidus (27%), and a small increase in basal binding in cerebellum (20%). As seen previously in Figures 3 and 4 , however, there were significant decreases in WIN 55212-2-stimulated [
35 S]GTP␥S binding in most brain regions in sections from chronic ⌬ 9 -THCtreated animals (Table 1) . For the acute group (Table 2) , no significant changes in either basal or WIN 55212-2-stimulated [ 35 S]GTP␥S binding were observed compared with controls.
Several independent methods were used to determine whether residual ⌬ 9 -THC in sections was potentially affecting the results of the study (data not shown). First, another set of brain sections from these animals was incubated with 1 M SR141716A, the cannabinoid antagonist. Results revealed that SR141716A blocked WIN 55212-2-stimulated binding in sections from both control and chronic ⌬ 9 -THC-treated rats but had no effect on basal [
35 S]GTP␥S binding in sections from either group. Therefore, there was not sufficient residual ⌬ 9 -THC acting as an agonist in these sections to affect the results. Another experiment assayed cannabinoid receptor binding in cerebellar membranes from both control and chronic ⌬ 9 -THC-treated rats, using the specific antagonist [ 3 H]SR141716A as a radioligand. Results (not shown) revealed that chronic ⌬ 9 -THC treatment had no effect on the -THC were present in these membranes and acted as a partial agonist, it would shift the WIN 55212-2 concentration-effect curve to the right and increase the EC 50 value of the full agonist (see Fig. 1 ). All of these results indicate that residual ⌬ 
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Our previous studies (Sim et al., 1995) showed that GABA Bstimulated [
35 S]GTP␥S binding could be localized autoradiographically with use of baclofen as an agonist. Because cannabi- 
